PRESS RELEASE
12 November 2025 08:45:00 CET

Cantargia presents Nomination Committee ahead of 2026 AGM

Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today provided notification that the Nomination Committee (NC) has been appointed ahead of the 2026 Annual General Meeting (AGM). It is composed of Arne Lööw (Fjärde AP-fonden), Henrick Schill, Lars H. Bruzelius (Brushamn Invest AB) and Magnus Persson (Chairman of the Board). The NC has been appointed in accordance with the guidelines established at the 2023 AGM.

As of September 30, 2025, the Nomination Committee represents a total of 13 per cent of the shares in Cantargia. In accordance with the guideline, Cantargia's largest shareholders have been offered to nominate a member. Första AP-fonden, Avanza Pension and The Invus Group have refrained from appointing a representative. Arne Lööw, representing the largest shareholder, will be the chairman of the NC.

The Annual General Meeting will be held on May 21, 2026, at Ideon Gateway, Scheelevägen 27, in Lund, Sweden.

The Nomination Committee's tasks for the AGM are to propose a Chairman for the AGM, members of the Board of Directors and Chairman of the Board of Directors, remuneration to the members and the chairman respectively and potential remuneration for committee and election of auditor, including principles of remuneration of the auditor. Finally, the NC will propose principles for appointing the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the NC to Cantargia AB, Att: Nomination Committee, Scheelevägen 27, 223 63 Lund, or by e-mail to **info@cantargia.com**. To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2026.

The Nomination Committee's proposals will be announced in the notice for the AGM and on Cantargia’s web site.

For further information, please contact
Magnus Persson, Chairman of the Board of Directors
Telephone: +46 46-275 62 60
E-mail: **info@cantargia.com**

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at **www.cantargia.com**.

Attachments

Cantargia presents Nomination Committee ahead of 2026 AGM